Atherosclerosis is present in about 50% of asymptomatic adults at middle age and in nearly all elderly individuals. The traditional diagnostic and treatment paradigm has addressed risk detection and reduction of binary events, including myocardial infarction (MI), stroke, and cardiovascular death. About 50% of all acute coronary syndromes occur in previously asymptomatic subjects, 90% of whom have modifiable risk factors; yet our current screening approaches fail to prevent the 1.2 million acute cardiovascular events that occur annually in the United States. In a patient with active disease, multiple treatment targets can be approached with a variety of lifestyle changes and medical therapy to render the disease quiescent in theory. A future approach may be interception of atherosclerosis before the identification of theoretical or actual risk of episodic events. This case review highlights use of advanced biomarkers and imaging to assess atherosclerotic disease activity in a 49-year-old asymptomatic woman who presents for evaluation after the death of her father from MI.

Download full-text PDF

Source

Publication Analysis

Top Keywords

atherosclerotic disease
8
disease activity
8
lipoproteins inflammatory
4
inflammatory biomarkers
4
biomarkers cardiovascular
4
cardiovascular imaging
4
imaging assessment
4
assessment atherosclerotic
4
disease
4
activity atherosclerosis
4

Similar Publications

Background: Established risk models may not be applicable to patients at higher cardiovascular risk with a measured Lp(a) (lipoprotein[a]) level, a causal risk factor for atherosclerotic cardiovascular disease.

Methods: This was a model development study. The data source was the Nashville Biosciences Lp(a) data set, which includes clinical data from the Vanderbilt University Health System.

View Article and Find Full Text PDF

Background: Dyslipidemia is a major risk factor for cardiovascular disease (CVD) and atherosclerotic CVD (ASCVD). The composite dietary antioxidant index (CDAI), an emerging measure of combined dietary antioxidant exposure, may provide insights into the relationship between diet and CVD/ASCVD outcomes. We aimed to explore the association between CDAI and the prevalence of CVD/ASCVD, as well as CVD mortality in individuals with dyslipidemia.

View Article and Find Full Text PDF

Background: Atherogenic index of plasma (AIP), a novel logarithmic index that combines fasting triglyceride and high-density lipoprotein cholesterol concentrations, is associated with the burden of atherosclerosis. This study aimed to evaluate the relationship between AIP and coronary artery disease (CAD) risk, severity, and prognosis in populations with and without established CAD.

Methods: PubMed, Embase, and Web of Science were systematically searched from the inception of each database to August 13, 2024.

View Article and Find Full Text PDF

Anthropometric and metabolic parameters associated with visceral fat in non-obese type 2 diabetes individuals.

Diabetol Metab Syndr

January 2025

Department of Endocrinology, The Second People's Hospital of Yunnan Province, The Affiliated Hospital of Yunnan University, Kunming, Yunnan, 650021, China.

Background And Aim: Visceral fat (VF) was proved to be a more precise predictor of atherosclerotic cardiovascular disease (ASCVD) risk in individuals with type 2 diabetes mellitus (T2DM) than body mass index (BMI) itself. Even when the BMI was normal, visceral fat area (VFA) ≥ 90 cm² could raise the ten-year risk of developing ASCVD. Therefore, it was worth evaluating the association of influencing factors with high VF in non-obese T2DM individuals.

View Article and Find Full Text PDF

Atherosclerosis, a chronic inflammatory condition characterized by plaque formation, often leads to instability, particularly under Type 2 diabetes mellitus (T2DM) conditions, which exacerbate cardiovascular risks. However, the molecular mechanisms underlying this process remain incompletely understood. In this study, we investigated the correlation between acute coronary syndrome (ACS) and serum levels of Nε-carboxyethyl-lysin (CEL), a prominent advanced glycation end product (AGE) elevated in T2DM, in a cohort of 225 patients with coronary artery disease.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!